Introduction

Innovation in pharmaceutical excipients goes beyond raw material production. Particle engineering, structural modification, and functional optimization are essential to improving excipient performance in pharmaceutical formulations.

At Westpoint Pharma, we have developed proprietary patented technologies for pharmaceutical mannitol, forming the technological foundation of our DESU^® Mannitol product portfolio.

Our manufacturing technologies incorporate secondary granulation and particle engineering processes to optimize particle morphology, powder flowability, compressibility, and formulation performance.

Our DESU^® Mannitol portfolio includes two main product categories: C Series (Crystalline Mannitol) and SD Series (Spray-Dried Mannitol). Both are supported by our proprietary technological development and patented manufacturing processes.

---

What Are the Patented Technologies Behind DESU^® Mannitol?

Westpoint Pharma has independently developed two patented technologies related to pharmaceutical mannitol processing and modification.

1. Preparation Method for Direct-Compression Mannitol

Patent No.: ZL202311578521.0

This patented technology relates to the processing of sugar alcohols and focuses on the preparation of mannitol particles with improved physical properties for direct compression applications.

The process involves mixing mannitol with a foaming agent to prepare an aqueous suspension, followed by centrifugal spray drying to produce approximately spherical mannitol particles.

The resulting particles feature a porous, lightweight, approximately spherical structure, providing several important powder characteristics:

Through this process, Westpoint Pharma develops functional mannitol particles designed for direct compression applications.

---

2. Preparation Method for Modified Mannitol for Pharmaceutical Excipients

Patent No.: ZL202411718105.0

This patented technology focuses on the functional modification of pharmaceutical mannitol through the combination of selected functional ingredients.

The process involves carefully selecting and optimizing the proportions of multiple components, such as:

• Polyethylene Glycol (PEG)
• Sodium Carboxymethyl Cellulose (CMC-Na)
• Cyclodextrin
• Nano-Silica
• Plant-Derived Microcrystalline Cellulose
• Chitosan

Through composite modification, this technology is designed to improve several important functional properties of mannitol and its performance in pharmaceutical formulations.

Different functional components contribute to different performance characteristics:

Solubility Optimization

Cyclodextrin and chitosan work synergistically to enhance solubility-related performance.

Powder Flowability

The incorporation of nano-silica can improve powder flow characteristics.

Formulation Performance

The composite modification approach is designed to enhance stability, bioavailability-related performance, and the formability and compressibility of pharmaceutical formulations.

Disintegration Control

The modified system provides the potential to adjust disintegration time across different formulation requirements, from immediate-release to sustained-release applications.

This technology expands the functional design possibilities of pharmaceutical mannitol beyond conventional powder processing.

---

How Do These Patented Technologies Support DESU^® Mannitol?

The two patented technologies provide the technical foundation for the secondary forming processes used in Westpoint Pharma's DESU^® Mannitol C Series and SD Series.

By controlling particle structure and optimizing material composition, we focus on improving the functional properties of pharmaceutical mannitol.

Our particle engineering approach addresses several important aspects of excipient performance:

These technologies reflect our commitment to developing pharmaceutical excipients through independent research, proprietary processes, and functional material engineering.

---

Why Does Patented Particle Engineering Matter in Pharmaceutical Excipients?

For pharmaceutical manufacturers, excipient selection is not determined by chemical composition alone.

Physical properties, particle morphology, and functional characteristics can significantly influence formulation development and manufacturing performance.

At Westpoint Pharma, we recognize that different pharmaceutical applications require different excipient characteristics.

Our patented mannitol technologies focus on two complementary development directions:

1. Particle Structure Engineering

By controlling the granulation and drying processes, we develop mannitol particles with tailored morphology, suitable bulk density, and favorable powder properties.

2. Functional Material Modification

By combining mannitol with selected functional ingredients, we explore additional opportunities to optimize solubility, stability, flowability, compressibility, and disintegration behavior.

These approaches allow Westpoint Pharma to continuously expand the functional possibilities of pharmaceutical mannitol.

---

Westpoint Pharma: Driving Pharmaceutical Excipient Innovation

As a pharmaceutical excipients manufacturer, Westpoint Pharma is committed to developing functional excipients through independent research, patented technologies, and advanced manufacturing processes.

Our DESU^® Mannitol portfolio represents our continued investment in particle engineering and pharmaceutical excipient innovation.

From crystalline mannitol to spray-dried mannitol, we focus on optimizing material properties to support different pharmaceutical formulation and manufacturing requirements.

Through the Westpoint Excipients platform, we aim to provide pharmaceutical manufacturers worldwide with reliable excipient products and technical support.

Explore our pharmaceutical excipient portfolio at www.westpointexcipients.com.